Current management and novel agents for malignant melanoma

33Citations
Citations of this article
67Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Advanced malignant melanoma remains a challenging cancer. Over the past year, there have been 3 agents approved for treatment of melanoma by Food and Drug Administration. These include pegylated interferon alpha-2b for stage III melanoma, vemurafenib for unresectable or metastatic melanoma with BRAF V600E mutation, and ipilimumab for treatment of unresectable or metastatic melanoma. This review will also update on the development of novel agents, including tyrosine kinase inhibitors and adoptive cellular therapy. © 2012 Lee et al; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Lee, B., Mukhi, N., & Liu, D. (2012). Current management and novel agents for malignant melanoma. Journal of Hematology and Oncology. https://doi.org/10.1186/1756-8722-5-3

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free